Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) accounts for 10% of hematologic malignancies. CLL is a malignancy of CD5+ B cells and it is characterized by the accumulation of small, mature-appearing neoplastic lymphocytes in the blood, bone marrow, and secondary lymphoid tissues. In the present case, a middle-...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-12-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/10/1/10 |
| _version_ | 1797543860089389056 |
|---|---|
| author | Dipnarine Maharaj Gayathri Srinivasan Maria M. Abreu Meng-Wei Ko Anahid Jewett Jacqueline Gouvea |
| author_facet | Dipnarine Maharaj Gayathri Srinivasan Maria M. Abreu Meng-Wei Ko Anahid Jewett Jacqueline Gouvea |
| author_sort | Dipnarine Maharaj |
| collection | DOAJ |
| description | Chronic lymphocytic leukemia (CLL) accounts for 10% of hematologic malignancies. CLL is a malignancy of CD5+ B cells and it is characterized by the accumulation of small, mature-appearing neoplastic lymphocytes in the blood, bone marrow, and secondary lymphoid tissues. In the present case, a middle-aged female patient with poor prognosis unmutated IGHV CLL achieved cytogenetic and molecular remission with minimal adverse events following six cycles of low dose recombinant human IL-2 (rIL-2) in combination with low dose targeted venetoclax. Personalized low dose rIL-2 in combination with either lenalidomide or venetoclax mediates natural killer stimulation and is an effective non-toxic immunotherapy administered in the outpatient setting for poor prognosis CLL. |
| first_indexed | 2024-03-10T13:51:08Z |
| format | Article |
| id | doaj.art-954135cf9bfc4762a4db1c5ae8479fb0 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T13:51:08Z |
| publishDate | 2020-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-954135cf9bfc4762a4db1c5ae8479fb02023-11-21T02:07:57ZengMDPI AGCells2073-44092020-12-011011010.3390/cells10010010Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic LeukemiaDipnarine Maharaj0Gayathri Srinivasan1Maria M. Abreu2Meng-Wei Ko3Anahid Jewett4Jacqueline Gouvea5The Maharaj Institute of Immune Regenerative Medicine, Boynton Beach, FL 33437, USAThe Maharaj Institute of Immune Regenerative Medicine, Boynton Beach, FL 33437, USAInstitute for NeuroImmune Medicine, Nova Southeastern University, Ft. Lauderdale, FL 33314, USADivision of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, UCLA, Los Angeles, CA 90095, USADivision of Oral Biology and Medicine, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, UCLA, Los Angeles, CA 90095, USAThe Maharaj Institute of Immune Regenerative Medicine, Boynton Beach, FL 33437, USAChronic lymphocytic leukemia (CLL) accounts for 10% of hematologic malignancies. CLL is a malignancy of CD5+ B cells and it is characterized by the accumulation of small, mature-appearing neoplastic lymphocytes in the blood, bone marrow, and secondary lymphoid tissues. In the present case, a middle-aged female patient with poor prognosis unmutated IGHV CLL achieved cytogenetic and molecular remission with minimal adverse events following six cycles of low dose recombinant human IL-2 (rIL-2) in combination with low dose targeted venetoclax. Personalized low dose rIL-2 in combination with either lenalidomide or venetoclax mediates natural killer stimulation and is an effective non-toxic immunotherapy administered in the outpatient setting for poor prognosis CLL.https://www.mdpi.com/2073-4409/10/1/10chronic lymphocytic leukemiacancer treatmentimmunotherapyinterleukin-2natural killer cells |
| spellingShingle | Dipnarine Maharaj Gayathri Srinivasan Maria M. Abreu Meng-Wei Ko Anahid Jewett Jacqueline Gouvea Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia Cells chronic lymphocytic leukemia cancer treatment immunotherapy interleukin-2 natural killer cells |
| title | Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia |
| title_full | Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia |
| title_fullStr | Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia |
| title_full_unstemmed | Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia |
| title_short | Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia |
| title_sort | molecular remission using low dose immunotherapy with minimal toxicities for poor prognosis ighv unmutated chronic lymphocytic leukemia |
| topic | chronic lymphocytic leukemia cancer treatment immunotherapy interleukin-2 natural killer cells |
| url | https://www.mdpi.com/2073-4409/10/1/10 |
| work_keys_str_mv | AT dipnarinemaharaj molecularremissionusinglowdoseimmunotherapywithminimaltoxicitiesforpoorprognosisighvunmutatedchroniclymphocyticleukemia AT gayathrisrinivasan molecularremissionusinglowdoseimmunotherapywithminimaltoxicitiesforpoorprognosisighvunmutatedchroniclymphocyticleukemia AT mariamabreu molecularremissionusinglowdoseimmunotherapywithminimaltoxicitiesforpoorprognosisighvunmutatedchroniclymphocyticleukemia AT mengweiko molecularremissionusinglowdoseimmunotherapywithminimaltoxicitiesforpoorprognosisighvunmutatedchroniclymphocyticleukemia AT anahidjewett molecularremissionusinglowdoseimmunotherapywithminimaltoxicitiesforpoorprognosisighvunmutatedchroniclymphocyticleukemia AT jacquelinegouvea molecularremissionusinglowdoseimmunotherapywithminimaltoxicitiesforpoorprognosisighvunmutatedchroniclymphocyticleukemia |